Ionis Pharmaceuticals, Inc. (IONS)
Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript
Ionis Pharmaceuticals, Inc. (IONS) Q1 2026 Earnings Call Transcript
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Tops Revenue Estimates
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.3 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.75 per share a year ago.
Why Is Ionis Pharmaceuticals (IONS) Down 7.9% Since Last Earnings Report?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock?
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug
IONS wins FDA priority review for zilganersen in rare Alexander disease, with a Sept. 22, 2026, decision date backed by strong phase III data.
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2026 Virtual CNS Forum Transcript
Algert Global LLC Grows Position in Ionis Pharmaceuticals, Inc. $IONS
Algert Global LLC grew its position in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) by 562.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 252,281 shares of the company's stock after purchasing an additional 214,191 shares during the period. Algert Global LLC
Ionis Pharmaceuticals, Inc. (IONS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at Leerink Global Healthcare Conference 2026 Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ionis Pharmaceuticals: Digesting Recent Events
Ionis Pharmaceuticals recently raised Tryngolza's peak revenue estimate to over $2 billion after strong sHTG data, which has triggered a large stock rally since September 2025. IONS projects over $4 billion in peak annual product revenue, $2 billion in royalties, and $6 billion in milestones from its robust pipeline and partnerships. Management guides for cash-flow breakeven by 2028, with initial FY2026 guidance and a strong balance sheet supporting continued clinical advancement.
